World's Best Scientists 2026 revealed!
Masakazu Toi

Masakazu Toi

D-Index & Metrics

Medicine

D-Index
99
Citations
48085
World Ranking
8449
National Ranking
218

Overview

Masakazu Toi is affiliated with Kyoto University in Japan and has a substantial body of work focused primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research predominantly addresses oncology, with specific concentration on breast cancer and related treatment methodologies.

The scientist's research topics encompass various areas including:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer-related Molecular Pathways
  • Breast Lesions and Carcinomas
  • Lung Cancer Research Studies

Masakazu Toi frequently publishes in several well-recognized venues, notably:

  • Cancer Research
  • Annals of Oncology
  • Breast Cancer
  • Journal of Clinical Oncology
  • Breast Cancer Research and Treatment

Their most recent published papers include:

  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021," 2021, Annals of Oncology
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer," 2023, New England Journal of Medicine
  • "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial," 2022, The Lancet Oncology
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer," 2022, Annals of Oncology

Collaboration is a notable feature of Masakazu Toi's research, working extensively with co-authors such as:

  • Norikazu Masuda
  • Satoshi Morita
  • Masahiro Takada
  • Shinji Ohno
  • Kosuke Kawaguchi

The combination of these collaborations and frequent publications in leading oncology journals reflects a focused career centered on cancer research, particularly breast cancer treatment and its molecular aspects. Their work contributes to clinical and pharmacological understanding through a multidisciplinary approach integrating genetics, molecular biology, and therapeutic strategies.

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

    Chikashi Nakanishi;Masakazu Toi

  • Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

    Takayuki Ueno;Masakazu Toi;Hisashi Saji;Mariko Muta

  • Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

    P. E. Vermeulen;G. Gasparini;S. B. Fox;Masakazu Toi

  • The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer

    Masakazu Toi;Seigo Hoshina;Toshiaki Takayanagi;Takeshi Tominaga

  • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

    Fabrice André;Ruth O'Regan;Mustafa Ozguroglu;Masakazu Toi

  • Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

    Masakazu Toi;Kazuo Inada;Hideo Suzuki;Takeshi Tominaga

  • Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

    David Cameron;Julia Brown;Rebecca Dent;Christian Jackisch

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma.

    Masakazu Toi;Takeshi Tominaga;Jitsuo Kashitani

  • Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Edith A. Perez;Carlos Barrios;Wolfgang Eiermann;Masakazu Toi

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

  • Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

    Hisashi Saji;Morio Koike M.D.;Takao Yamori;Shigehira Saji M.D.

  • Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

Frequent Co-Authors

Hiroji Iwata
Hiroji Iwata Aichi Cancer Center
Satoshi Morita
Satoshi Morita Kyoto University
Kaori Togashi
Kaori Togashi Kyoto University
Hironobu Sasano
Hironobu Sasano Tohoku University
Hiroshi Ishiguro
Hiroshi Ishiguro Osaka University
George W. Sledge
George W. Sledge Stanford University
Naoki Yamamoto
Naoki Yamamoto Kyoto University
Yasuo Ohashi
Yasuo Ohashi Chuo University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Yoshimasa Tanaka
Yoshimasa Tanaka Nagasaki University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA, you may also be interested in allied online programs that offer flexible pathways into healthcare careers. Pursuing a health administration degree is a smart option for those who want to lead within hospitals or medical facilities without becoming a physician.

For those ready to move into advanced healthcare leadership roles, there are cheapest online mha programs that balance affordability with graduate-level expertise. Nurses aiming to reach top clinical positions might consider the best online bsn to dnp programs, allowing career advancement while continuing to work.

If pharmacy fascinates you, enrolling in a pharmacy school online accredited program is now more accessible than ever, combining rigorous academic standards with distance learning convenience.

These degree options enable you to join the healthcare sector through diverse routes, with online flexibility to meet your needs and career goals. Consider them as alternative or complementary pathways alongside medical school.

Best Scientists Citing Masakazu Toi

Trending Scientists

Recently Published Articles